SCHEMBL9608441

SCHEMBL9608441

Oc1ccccc1-c1nc(-c2ccc(C(F)(F)F)cc2)nc(-c2ccc(C(F)(F)F)cc2O)n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHUK O15111 1/20 0.60
TXNRD1 Q16881 1/20 0.60
NOX4 Q9NPH5 1/20 0.60
POLB P06746 3/20 0.54
LMNA P02545 1/20 0.54
KDM4E B2RXH2 1/20 0.52
ALDH1A1 P00352 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP2C19 P33261 1/20 0.52
HSD17B10 Q99714 1/20 0.52
TSHR P16473 2/20 0.51
ADORA3 P0DMS8 2/20 0.51
ALOX15 P16050 1/20 0.51
ADORA2A P29274 1/20 0.51
ADORA2B P29275 1/20 0.51
ADORA1 P30542 1/20 0.51
KEAP1 Q14145 1/20 0.48
MAPK1 P28482 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
ALOX5AP P20292 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9608390 0.94 CHUK (0.67) CHUKTXNRD1NOX4POLBLMNA
SCHEMBL9608470 0.89 CHUK (0.55) CHUKTXNRD1NOX4POLBLMNA
SCHEMBL15910009 0.87 CHUK (0.53) CHUKTXNRD1NOX4POLBLMNA
SCHEMBL15779812 0.87 CHUK (0.53) CHUKTXNRD1NOX4POLBLMNA
SCHEMBL9609230 0.86 CHUK (0.52) CHUKTXNRD1NOX4POLBLMNA
SCHEMBL9608437 0.85 MAPT (0.51) CHUKTXNRD1NOX4POLBLMNA
SCHEMBL9608484 0.84 POLB (0.55) CHUKTXNRD1NOX4POLBLMNA
SCHEMBL14070317 0.83 KIF11 (0.52) CHUKTXNRD1NOX4POLBLMNA
SCHEMBL9609271 0.83 POLB (0.54) CHUKTXNRD1NOX4POLBLMNA
SCHEMBL12754975 0.82 CYP1A2 (0.49) CHUKTXNRD1NOX4POLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160200933-A1 RESIN COMPOSITION, PROTECTIVE FILM FOR POLARIZING PLATE, POLARIZING PLATE, AND DISPLAY FUJIFILM CORPORATION (JP) 2016-07-14 US disclosed
US-8957140-B2 Triazine derivative, ultraviolet absorber, and resin composition FUJIFILM CORPORATION (JP) 2015-02-17 US disclosed
US-8957140-B2 Triazine derivative, ultraviolet absorber, and resin composition FUJIFILM CORPORATION (JP) 2015-02-17 US disclosed
US-8748520-B2 Polycarbonate resin composition containing triazine compound and molded article using the same FUJIFILM CORPORATION (JP) 2014-06-10 US disclosed
US-8623990-B2 Polyester resin composition FUJIFILM CORPORATION (JP) 2014-01-07 US disclosed
US-8623990-B2 Polyester resin composition FUJIFILM CORPORATION (JP) 2014-01-07 US disclosed
US-20120301696-A1 POLYESTER RESIN COMPOSITION FUJIFILM CORPORATION (JP) 2012-11-29 US disclosed
US-20120301696-A1 POLYESTER RESIN COMPOSITION FUJIFILM CORPORATION (JP) 2012-11-29 US disclosed
US-20120136098-A1 NEW TRIAZINE DERIVATIVE, ULTRAVIOLET ABSORBER, AND RESIN COMPOSITION FUJIFILM CORPORATION (JP) 2012-05-31 US disclosed
US-20120136098-A1 NEW TRIAZINE DERIVATIVE, ULTRAVIOLET ABSORBER, AND RESIN COMPOSITION FUJIFILM CORPORATION (JP) 2012-05-31 US disclosed
US-20110077331-A1 POLYCARBONATE RESIN COMPOSITION CONTAINING TRIAZINE COMPOUND AND MOLDED ARTICLE USING THE SAME FUJIFILM CORPORATION (JP) 2011-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120136098-A1 NEW TRIAZINE DERIVATIVE, ULTRAVIOLET ABSORBER, AND RESIN COMPOSITION C1R, RPSA, H1-2 CHUK 1494/4885TXNRD1 1279/4885NOX4 2643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.